Targeting cIAPs attenuates CCl 4 -induced liver fibrosis by increasing MMP9 expression derived from neutrophils

• Published in: Life sciences (1973) 2022-01, Vol.289, p.120235
• Main Authors: Wu, Yi, Lu, Suwen, Huang, Xuan, Liu, Yuanyuan, Huang, Kuiyuan, Liu, Ziying, Xu, Weikang, Zhu, Wei, Hou, Jinlin, Liu, Hongyan, Zhang, Xiaoyong
• Format: Article
• Language: English
• Subjects: Animals; Baculoviral IAP Repeat-Containing 3 Protein - genetics; Baculoviral IAP Repeat-Containing 3 Protein - metabolism; Carbon Tetrachloride Poisoning - genetics; Carbon Tetrachloride Poisoning - metabolism; Carbon Tetrachloride Poisoning - pathology; Gene Deletion; Gene Expression Regulation, Enzymologic; Humans; Liver Cirrhosis - genetics; Liver Cirrhosis - metabolism; Liver Cirrhosis - pathology; Male; Matrix Metalloproteinase 9 - biosynthesis; Matrix Metalloproteinase 9 - genetics; Mice; Mice, Knockout; Neutrophils - metabolism; Neutrophils - pathology
• ISSN: 1879-0631

Liver fibrosis is a growing public health concern without effective medical treatment. Recent reports have indicated that inhibitors of apoptosis proteins (IAPs) were potential targets for idiopathic pulmonary fibrosis therapy. However, their roles have not been well identified in liver fibrosis. The expression of IAPs were examined in human liver tissue and experimental mouse models. Liver fibrosis in CCl -induced mouse models were investigated by Sirius red staining, RT-PCR, Western blotting after hepatocytes-specific cIAP2 knockout or IAPs inhibitor APG-1387 treatment. The underlying molecular mechanism of APG-1387 action was explored by apoptosis analysis, matrix metalloprotein 9 (MMP9) inhibition, neutrophils depletion, and CC Motif Chemokine Ligand 5 (CCL5) gene knockout in vitro and in vivo. Our study showed that increased expression of cIAP2 was associated with liver fibrosis severity in liver tissues. Deletion of cIAP2 from hepatocytes or degrading cIAPs by APG-1387 ameliorated liver fibrosis induced by CCl . APG-1387 treatment exhibited increased expression of MMP9 and resulted in higher ratio of MMP9 to tissue inhibitor of metalloproteinase-1. MMP9 was mainly derived from CCL5 chemotactic neutrophils. Further, MMP9 inhibition by CTT peptide, neutrophil depletion by Ly6G antibody or CCL5 deficiency blocked the anti-fibrotic effects of APG-1387 in vivo. These results suggested that cIAPs, especially cIAP2, might play a novel role in the pathogenesis of liver fibrosis, and targeting cIAPs represented a promising therapeutic strategy for liver fibrosis by increasing MMP9 expression induced by CCL5 chemotactic neutrophils.